MDT

100.99

-0.45%↓

A

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

A

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

A

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

A

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

A

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

Search

Twist Bioscience Corp

Gesloten

SectorGezondheidszorg

42.96 -4.87

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

42.36

Max

43.13

Belangrijke statistieken

By Trading Economics

Inkomsten

-48M

-27M

Verkoop

3M

99M

Winstmarge

-27.41

Werknemers

979

EBITDA

3.2M

-21M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

-3.94% downside

Dividenden

By Dow Jones

Volgende Winsten

2 feb 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

669M

2.5B

Vorige openingsprijs

47.83

Vorige sluitingsprijs

42.96

Nieuwssentiment

By Acuity

50%

50%

142 / 352 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Twist Bioscience Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

23 jan 2026, 18:41 UTC

Winsten

SLB Readies Rapid Expansion in Venezuela -- 2nd Update

24 jan 2026, 09:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

24 jan 2026, 09:20 UTC

Marktinformatie
Winsten

Tech, Media & Telecom Roundup: Market Talk

24 jan 2026, 09:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

24 jan 2026, 09:20 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

24 jan 2026, 06:18 UTC

Acquisities, Fusies, Overnames

Our Boston Scientific Pick Has Stumbled. Acquiring Penumbra Will Help the Stock. -- Barrons.com

23 jan 2026, 22:30 UTC

Marktinformatie

Global Equities Roundup: Market Talk

23 jan 2026, 22:30 UTC

Marktinformatie

Trump Seen Using Canada's EV Deal With China to Extract Concessions -- Market Talk

23 jan 2026, 22:03 UTC

Winsten

These Stocks Are Today's Movers: Intel, AMD, Capital One, Booz Allen, BitGo, Fortinet, and More -- Barrons.com

23 jan 2026, 21:52 UTC

Winsten
Acquisities, Fusies, Overnames

GE Aerospace's Earnings Worried the Market. What CEO Larry Culp Says. -- Barrons.com

23 jan 2026, 21:50 UTC

Marktinformatie
Winsten

Tech, Media & Telecom Roundup: Market Talk

23 jan 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

23 jan 2026, 21:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

23 jan 2026, 21:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

23 jan 2026, 21:39 UTC

Winsten

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- 5th Update

23 jan 2026, 21:15 UTC

Acquisities, Fusies, Overnames

Eaton Completes Acquisition Of Ultra PCS Limited, Expanding Capabilities And Solutions For Next-generation Aerospace And Defense Markets >ETN

23 jan 2026, 21:12 UTC

Winsten

CSX Stock Rises After Earnings Miss Estimates. It's the Outlook. -- Barrons.com

23 jan 2026, 20:31 UTC

Winsten

These Stocks Are Today's Movers: Intel, AMD, Capital One, Booz Allen, BitGo, Fortinet, and More -- Barrons.com

23 jan 2026, 20:12 UTC

Marktinformatie

Oil Futures Rebound on Iran, Russia-Ukraine Risk -- Market Talk

23 jan 2026, 20:07 UTC

Marktinformatie

U.S. Natural Gas Posts Record Weekly Gain on Winter Storm -- Market Talk

23 jan 2026, 19:36 UTC

Marktinformatie

Dollar Weakens Against Yen Amid Intervention Chatter -- Market Talk

23 jan 2026, 19:30 UTC

Marktinformatie
Winsten

Intel's Stock Has Limited Catalysts Ahead, Analysts Say -- Market Talk

23 jan 2026, 19:18 UTC

Marktinformatie

Gold and Silver Step Up to More Records -- Market Talk

23 jan 2026, 19:15 UTC

Winsten

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- 4th Update

23 jan 2026, 18:53 UTC

Marktinformatie

U.S. Oil Rig Count Rises By 1 to 411 -- Market Talk

23 jan 2026, 18:21 UTC

Winsten

Week's Best: Schwab's Assets and Profits Keep Climbing -- Barrons.com

23 jan 2026, 18:19 UTC

Marktinformatie

Intel Seen as Increasingly Confident on Demand -- Market Talk

23 jan 2026, 17:59 UTC

Winsten

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- 3rd Update

23 jan 2026, 17:57 UTC

Marktinformatie

Intel Could Sign Deals With Big Tech Players for 14A -- Market Talk

23 jan 2026, 17:57 UTC

Marktinformatie

Global Equities Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Twist Bioscience Corp Prognose

Koersdoel

By TipRanks

-3.94% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 41.25 USD  -3.94%

Hoogste 43 USD

Laagste 39 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Twist Bioscience Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

5

Buy

0

Hold

0

Sell

Technische score

By Trading Central

31.56 / 38.6884Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

142 / 352 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat